T1	Participants 96 159	elderly adults with newly diagnosed acute myelogenous leukemia.
T2	Participants 204 273	elderly adults with newly diagnosed acute myelogenous leukemia (AML).
T3	Participants 452 559	84 adults (age range, 70-90 years; median, 76 years) who were not candidates for conventional chemotherapy.
